NASDAQ:RCKTW Rocket Pharmaceuticals (RCKTW) Stock Price, News & Analysis $0.04 +0.00 (+5.09%) As of 08/7/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock About Rocket Pharmaceuticals Stock (NASDAQ:RCKTW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rocket Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.03▼$0.0450-Day Range$0.03▼$0.1452-Week Range$0.02▼$0.15Volume13,300 shsAverage Volume23,131 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare and often fatal inherited diseases. The company utilizes ex vivo lentiviral vector-based approaches to deliver functional copies of genes into patients’ hematopoietic stem cells. By targeting the underlying genetic defects, Rocket aims to provide potentially curative treatments for disorders that currently rely on lifelong supportive care or conventional interventions. Rocket’s pipeline comprises multiple programs in various stages of development, including treatments for Fanconi anemia, primary immune deficiencies such as PNP deficiency and ADA-SCID, as well as metabolic and cardiac conditions like Danon disease and Barth syndrome. Several of these programs have advanced into clinical trials, reflecting the company’s emphasis on accelerating therapies from preclinical proof-of-concept through regulatory milestones. Founded in 2013 and headquartered in New York, Rocket Pharmaceuticals operates primarily in the United States while collaborating with academic and clinical partners across North America and Europe. The company is led by a management team with extensive experience in gene therapy, hematology and rare disease drug development, and it continues to expand its manufacturing and clinical infrastructure to support future growth.AI Generated. May Contain Errors. Read More Receive RCKTW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKTW Stock News HeadlinesRocket Pharmaceuticals Restructures, Lays Off 30% of Workforce to Focus on Cardiovascular, LAD-I Gene TherapiesAugust 1, 2025 | msn.comRocket Pharmaceuticals Gets FDA Designation to Speed Heart-Disease Treatment DevelopmentJuly 17, 2025 | marketwatch.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701July 15, 2025 | msn.comGlorilla to headline Z107.9 Summer Jam 2025 at Rocket ArenaJuly 15, 2025 | msn.comAustralia Fires First HIMARS Long-Range Rocket in War Game With USJuly 14, 2025 | usnews.comBlackpearl tech firm moves to buy US company B2B RocketJuly 13, 2025 | msn.comFormer Laval Rocket Defenseman Noel Hoefenmayer Signs In RussiaJuly 13, 2025 | sports.yahoo.comSee More Headlines RCKTW Stock Analysis - Frequently Asked Questions How have RCKTW shares performed this year? Rocket Pharmaceuticals' stock was trading at $0.0343 at the start of the year. Since then, RCKTW stock has increased by 14.3% and is now trading at $0.0392. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKTW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RCKTW CIK1281895 Webwww.rocketpharma.com Phone16464409100FaxN/AEmployees240Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:RCKTW) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.